R&D
KyDo Therapeutics GmbH (KyDo) is a preclinical-stage biotechnology company committed to developing novel covalent- allosteric small molecule inhibitors with the potential to become first-in-class oncology drugs. KyDo was jointly founded by Lead Discovery Center GmbH (LDC) together with scientists from the Rauh Lab at TU Dortmund University.
At KyDo Therapeutics, we are redefining cancer treatment with our pioneering approach of targeting a key cancer driver with innovative precision medicine. Our focus on covalent-allosteric inhibitors places us at the forefront of an exciting and rapidly evolving area of drug discovery with immense potential to enhance efficacy, minimise side effects and enable new combination therapies that are urgently required.
Our approach represents a paradigm shift in cancer therapy.
First pioneered at TU Dortmund University, covalent-allosteric
modulation has been shown to overcome the resistance mechanisms
that currently limit treatment effectiveness. In close
collaboration with trusted partners, we are now translating
this scientific innovation at KyDo into real-world therapeutic
applications with the potential to meaningfully improve the
lives of cancer patients.
KyDo Therapeutics is driven by a dedicated and experienced team and is committed to turning cutting-edge science into next-generation medicines — accelerating progress where it's needed most.
PIPELINE
coming soon...